ArticleeLife2021
The development of
Open access · goldAbstract read
In one paragraph
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review.Analytical biochemistry · 2022Pooled it
- Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting.Molecular pharmaceutics · 2026Article
- Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape.PLoS pathogens · 2026Article
- Gut-Brain Inflammation and Disrupted Homeostasis Due to Activation of Mast Cells and Microglia.International journal of molecular sciences · 2026Review
- A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections.PLoS pathogens · 2026Article
- Long-Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection.Advanced nanobiomed research · 2025Article
- Humanized VHH-hFc Fusion Proteins Targeting the L-HN Fragment of Tetanus Toxin Provided Protection In Vivo.Antibodies (Basel, Switzerland) · 2025Article
- Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.PLoS pathogens · 2024Article
- Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate.PLoS pathogens · 2024Article
- Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.Journal of virology · 2024Article
- Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants.PLoS pathogens · 2024Article
- Structure-guided in vitro evolution of nanobodies targeting new viral variants.PLoS pathogens · 2024Article
- Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.Journal of nanobiotechnology · 2024Review
- Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer.Bioconjugate chemistry · 2024Article
- Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications.Biosensors · 2024Review
- Article
- Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.Journal of virology · 2023Article
- Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein.eLife · 2023Article
- Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein.Fish & shellfish immunology · 2023Article
- Identification of a Linear B Cell Epitope on p54 of African Swine Fever Virus Using Nanobodies as a Novel Tool.Microbiology spectrum · 2023Article
Corrections and comments
- Update of
Authors and funding
15 authors at 4 institutions in 1 country.
Gang Ye *Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States.ORCID 0000-0001-6034-2174
Joseph Gallant *Department of Pharmacology, University of Minnesota, Minneapolis, United States.ORCID 0000-0003-4943-1744
Jian Zheng *Department of Microbiology and Immunology, University of Iowa, Iowa City, United States.
Christopher MasseyInstitutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, United States.
Ke ShiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, United States.
Wanbo TaiLaboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, United States.ORCID 0000-0002-9864-8993
Abby OdleDepartment of Microbiology and Immunology, University of Iowa, Iowa City, United States.
Molly VickersDepartment of Microbiology and Immunology, University of Iowa, Iowa City, United States.
Jian ShangDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States.
Yushun WanDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States.
Lanying DuLaboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, United States.
Hideki AiharaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, United States.ORCID 0000-0001-7508-6230
Stanley PerlmanDepartment of Microbiology and Immunology, University of Iowa, Iowa City, United States.
Aaron LeBeauDepartment of Pharmacology, University of Minnesota, Minneapolis, United States.
Fang LiDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States.ORCID 0000-0002-1958-366X
University of Minnesota · USUniversity of Iowa · USNew York Blood Center · USThe University of Texas Medical Branch at Galveston · US
Funding
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI MALCOLM S. CAPEL · 2018 to 2026
$34.2MSARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5MStructural studies of viral replication and invasionR35GM118047 · NIGMS · UNIVERSITY OF MINNESOTA · PI Hideki Aihara · 2016 to 2026
$6.3MReceptor recognition mechanisms of coronavirusesR01AI089728 · NIAID · UNIVERSITY OF MINNESOTA · PI Fang Li, Timothy Patrick Sheahan · 2010 to 2026
$4.7MRole of eicosanoids in pathogenic human CoV infectionsR01AI129269 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 2016 to 2026
$4.7MNovel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronavirusesR01AI157975 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING, LI, FANG · 2020 to 2025
$3.9MPixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0MNIAID NIH HHS P01 AI060699NIAID NIH HHS R01 AI089728NIAID NIH HHS R01 AI129269NIAID NIH HHS R01 AI157975NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R35 GM118047NIH HHS R01AI089728NIH HHS R01AI157975NIH HHS R35GM118047NIH HHS S10 OD021527
Abstract
Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody),
Indexed as
COVID-19 Drug TreatmentAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19HEK293 CellsHumansMaleMiceMice, Inbred C57BLMice, TransgenicModels, MolecularPandemicsProtein BindingProtein ConformationAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralReceptors, VirusSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2animal modelCOVID-19crystal structuresdrug pharmacokineticsinfectious diseasemicrobiologysingle-chain antibody from camelidsspike protein receptor-binding domainvirusvirus neutralization
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.